Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

ClinicalTrials.gov ID: NCT04684511

Public ClinicalTrials.gov record NCT04684511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy (HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.

Study identification

NCT ID
NCT04684511
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Enrollment
2 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 1, 2021
Primary completion
Sep 27, 2022
Completion
Sep 27, 2022
Last update posted
Oct 26, 2022

2021 – 2022

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Orthopedic Hospital DBA Orthopedic Hemophilia Treatment Center Los Angeles California 90007
Center for Inherited Blood Disorders Orange California 92868
UC Davis Children's Hospital Sacramento California 95817
University of Colorado Hemophilia & Thrombosis Center Aurora Colorado 80045
Georgetown University Hospital - Medstar Washington D.C. District of Columbia 20007
University of Florida - Shands Gainesville Florida 32610
Clinical Trial Services, Corp Miami Florida 33144
Anchor Medical Research, LLC Miami Florida 33176
Rush University Medical Center Chicago Illinois 60612
University of Iowa Hospitals & Clinics Iowa City Iowa 52242
Louisiana Center for Bleeding and Clotting Disorders New Orleans Louisiana 70112
Johns Hopkins University Baltimore Maryland 21205
ECMC Hospital Buffalo New York 14202
Icahn School of Medicine at Mount Sinai. New York New York 10029
East Carolina University Greenville North Carolina 27858
Rainbow Babies and Children's Hospital Cleveland Ohio 44106
Oregon Health & Science University Portland Oregon 97239
North Texas Comprehensive Hemophilia Center Dallas Texas 75390
Gulf States Hemophilia and Thrombophilia Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04684511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 26, 2022 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04684511 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →